Nexplanon (Etonogestrel)

Etonogestrel, the active ingredient in Nexplanon, is a progestin (synthetic progesterone) presented as a 68 mg implantable subcutaneous rod for subcutaneous use. It prevents pregnancy by providing continuous hormonal contraception for women of reproductive age and is approved for long‑acting reversible contraception in the European market.

GNH USA supplies Nexplanon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory‑approved batches for global distribution. The firm also offers comprehensive logistics support, including customs clearance and temperature‑controlled shipping where required.

Etonogestrel, a synthetic progestin, is indicated for hormonal contraception in women. - Prevention of pregnancy: provides continuous release of progestin to inhibit ovulation and create cervical mucus changes that prevent fertilization for up to three years. - Family planning: allows women to plan and space pregnancies without daily adherence, supporting reproductive autonomy and reducing unintended pregnancies. - Long‑acting reversible contraception: offers a single‑procedure implant lasting up to three years, reducing the need for frequent dosing and improving compliance.

Etonogestrel may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Irregular bleeding or spotting - Headache - Acne - Breast tenderness

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Infection at the insertion site - Ectopic pregnancy if contraceptive failure occurs

Prior to implantation, clinicians should evaluate patients for contraindications and counsel on safe use. - Confirm non‑pregnancy: verify the patient is not pregnant before insertion. - Review thromboembolic history: avoid use in women with a history of blood clots or clotting disorders. - Assess liver function: contraindicated in severe hepatic impairment. - Evaluate medication interactions: consider drugs that may reduce contraceptive efficacy. - Counsel on menstrual changes: inform patients that irregular bleeding is common. - Store at ambient temperature: keep the implant in its original packaging, protect from moisture and direct sunlight.

Etonogestrel’s contraceptive effectiveness can be altered by concomitant medicines that affect hormone metabolism or protein binding.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin, phenobarbital): may markedly reduce hormone levels. - Rifampin or other strong CYP3A4 inducers: can decrease contraceptive efficacy. - Protease inhibitors used in HIV therapy: may increase hormone concentrations and risk of side effects.

Moderate Interactions (Monitor Closely): - Antibiotics such as tetracycline or metronidazole: may slightly lower effectiveness. - St. John’s wort herbal supplement: may modestly reduce plasma etonogestrel levels. - Antifungal agents (e.g., ketoconazole): can increase hormone levels, requiring monitoring.